Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Cytokinetics, Inc.    CYTK

SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

CYTOKINETICS : Announces Phase I and Phase IIa Clinical Trial Results for Omecamtiv Mecarbil Published in the Journal Lancet

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/19/2011 | 02:40pm CET
Results from These Trials Form the Basis For Ongoing Phase IIb Activities in Collaboration with Amgen

South San Francisco, CA - August 19, 2011

omecamtiv mecarbil, a novel cardiac myosin activator, in the August 20, 2011 issue of the journal Lancet. These two manuscripts present data regarding the safety, tolerability, pharmacokinetics and pharmacodynamic effects of this investigational drug candidate from a Phase I first-time-in-humans clinical trial in healthy volunteers and a Phase IIa clinical trial in stable heart failure patients, each sponsored by Cytokinetics. Together, these publications provide evidence for the translation into humans of this unique mechanistic approach to activating cardiac muscle contractility and support the further development of omecamtiv mecarbil as a potential treatment for heart failure. Amgen Inc. holds an exclusive, worldwide (excluding Japan) license to omecamtiv mecarbil and related compounds, subject to specified development and commercialization participation rights of Cytokinetics.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CYTOKINETICS, INC.
02/17 CYTOKINETICS : beats 4Q profit forecasts
02/16 CYTOKINETICS INC : Results of Operations and Financial Condition, Financial Stat..
02/16 Cytokinetics, Inc. Reports Fourth Quarter 2016 Financial Results
02/13CYTOKINETICS, INC. : annual earnings release
02/03 Cytokinetics to Announce Fourth Quarter Results on February 16, 2017
02/03 CYTOKINETICS : and Royalty Pharma Announce $100 Million Transaction for Omecamti..
02/02 CYTOKINETICS INC : Entry into a Material Definitive Agreement, Unregistered Sale..
02/02 Cytokinetics and Royalty Pharma Announce $100 Million Transaction for Omecamt..
2016 Cytokinetics Added to Nasdaq Biotechnology Index
2016 CYTOKINETICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND R..
More news
Sector news : Bio Therapeutic Drugs
02/22 Genmab and J&J's cancer drug set for blockbuster sales this year
02/21 Icahn buys Bristol-Myers shares, adding to activist pressure
02/21DJBristol-Myers Expands Board, Boosts Buybacks Amid Activist Pressure
02/16 How Sanofi lost out to J&J in $30 billion battle for Actelion
02/14 Gilead challenges GSK with strong HIV drug data
More sector news : Bio Therapeutic Drugs
Advertisement
Financials ($)
Sales 2017 45,9 M
EBIT 2017 -87,8 M
Net income 2017 -76,7 M
Debt 2017 -
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales 2017 9,30x
Capi. / Sales 2018 5,73x
Capitalization 427 M
More Financials
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 19,3 $
Spread / Average Target 83%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Robert I. Blum President, Chief Executive Officer & Director
L. Patrick Gage Chairman
Barabari Sharon A. Surrey Chief Financial Officer, Secretary & Executive VP
Andrew A. Wolff Chief Medical Officer & Senior Vice President
Fady Ibraham Malik Executive Vice President-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CYTOKINETICS, INC.427
AMGEN, INC.18.42%127 119
CELGENE CORPORATION3.19%92 788
GILEAD SCIENCES, INC.-3.24%90 681
REGENERON PHARMACEUTIC..1.23%39 273
ACTELION LTD22.45%28 907
More Results